Washington University

University of South Florida

Other

Elan Pharmaceuticals, Inc.

Alison M Goate

Alan Pestronk

Robert H Baloh

Nigel J Cairns

Michael A Gitcho

John A Hardy

Michael J Mullan

Dennis G Ballinger

Anthony L Hinrichs

Jen Chuan Wang

Peter Heutink

Michael John Owen

Marie-Christine Chartier-Harlin

John Anthony Hardy

John Rice

Frank Scott Saccone

Laura Jean Bierut

Michael L Hutton

Stuart M Brown

Karel Konvicka

The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an array comprising the nucleic acids and peptides of the invention.

Sequences associated with TDP-43 proteinopathies and methods of using the same

The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an army comprising the nucleic acids and peptides of the invention.

Correlations between polymorphisms and addiction are provided. Methods of diagnosing, prognosing, and treating addiction are provided. Systems and kits for diagnosis, prognosis and treatment of addiction are provided. Methods of identifying addiction modulators are also described.

Markers for addiction

Isolated nucleic acid molecules that include a tau gene sequence are described. The tau gene sequences have a mutation linked to a Tau pathology. Transgenic non-human mammals containing a Tau pathology also are also described.

Pathogenic tau mutations

Model systems of Alzheimer's disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposition to Alzheimer's disease are also disclosed.

Transgenic mouse expressing an APP-FAD DNA sequence

A method of detecting polymorphisms in the S182 gene by detecting mutations in the S182 gene using selected mismatched PCR primers comprising sequences derived from intronic sequences of the S182 gene is provided. A method of identifying an individual susceptible to late onset Alzheimer's Disease is also provided.

Method for elucidation and detection of polymorphisms, splice variants,

The invention provides novel mutant S182 sequences, methods of diagnosing Alzheimer's disease using these novel mutant S182 genes, a model system for Alzheimer's disease comprising a mutant S182 gene, and methods of identifying mutations in genes homologous to the S182 gene.

Mutant S182 genes

Growing community of inventors

St. Louis, MO, United States of America

Alison M Goate